SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Matthew Zibelman, Peter Barth, Elizabeth Handorf, Marc C. Smaldone, Alexander Kutikov, Robert G. Uzzo, Marijo Bilusic, Elizabeth R. Plimack, Yu-Ning Wong, Daniel M. Geynisman, A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite, Clinical Genitourinary Cancer, 2015, 13, 2, 142

    CrossRef

  2. 2
    Laurence Albiges, Toni Choueiri, Bernard Escudier, Matthew Galsky, Dan George, Fabian Hofmann, Thomas Lam, Robert Motzer, Peter Mulders, Camillo Porta, Thomas Powles, Cora Sternberg, Axel Bex, A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer, European Urology, 2015, 67, 1, 100

    CrossRef

  3. 3
    Shelize Khakoo, Alexandros Georgiou, Ian Chau, Clinical trial end points relevant to patients and society for rare cancers, Clinical Investigation, 2015, 5, 6, 599

    CrossRef

  4. 4
    K. R. Johnson, W. Liauw, M. N. D. Lassere, Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review, Annals of Oncology, 2015, 26, 3, 485

    CrossRef

  5. 5
    Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan A. Ledermann, Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials, Cancer, 2015, 121, 11
  6. 6
    Emilio Bria, Francesco Massari, Francesca Maines, Sara Pilotto, Maria Bonomi, Camillo Porta, Sergio Bracarda, Daniel Heng, Daniele Santini, Isabella Sperduti, Diana Giannarelli, Francesco Cognetti, Giampaolo Tortora, Michele Milella, Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis, Critical Reviews in Oncology/Hematology, 2015, 93, 1, 50

    CrossRef

  7. 7
    S. Négrier, A.G. Bushmakin, J.C. Cappelleri, B. Korytowsky, R. Sandin, C. Charbonneau, M.D. Michaelson, R.A. Figlin, R.J. Motzer, Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma, European Journal of Cancer, 2014, 50, 10, 1766

    CrossRef

  8. 8
    Bernard Escudier, Daniel Y.C. Heng, Arthur Smyth-Medina, Camillo Porta, Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma, Clinical Genitourinary Cancer, 2014, 12, 1, 1

    CrossRef

  9. 9
    Husain K. Khambati, Toni K. Choueiri, Christian K. Kollmannsberger, Scott North, George A. Bjarnason, Ulka N. Vaishampayan, Lori Wood, Jennifer J. Knox, Min-Han Tan, Mary J. MacKenzie, Frede Donskov, Brian I. Rini, Daniel Y.C. Heng, Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population, Clinical Genitourinary Cancer, 2014, 12, 5, 354

    CrossRef

  10. 10
    Jose G. Monzon, Daniel Y. C. Heng, Management of metastatic kidney cancer in the era of personalized medicine, Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 2, 85

    CrossRef

  11. 11
    Susan Halabi, Brian Rini, Bernard Escudier, Walter M. Stadler, Eric J. Small, Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma, Cancer, 2014, 120, 1
  12. 12
    Andreas Becker, Christian Eichelberg, Maxine Sun, Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?, Cancer, 2014, 120, 1
  13. 13
    Nils Kroeger, Toni K. Choueiri, Jae-Lyn Lee, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Sandy Srinivas, Ulka N. Vaishamayan, Sun-Young Rha, Sumanta K. Pal, Takeshi Yuasa, Frede Donskov, Neeraj Agarwal, Min-Han Tan, Aristotelis Bamias, Christian K. Kollmannsberger, Scott A. North, Brian I. Rini, Daniel Y.C. Heng, Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy, European Urology, 2014, 65, 6, 1086

    CrossRef

  14. 14
    Oriana Ciani, Sarah Davis, Paul Tappenden, Ruth Garside, Ken Stein, Anna Cantrell, Everardo D. Saad, Marc Buyse, Rod S. Taylor, VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS, International Journal of Technology Assessment in Health Care, 2014, 30, 03, 312

    CrossRef

  15. 15
    Toni K. Choueiri, Suchun Cheng, Angela Q. Qu, Jaromir Pastorek, Michael B. Atkins, Sabina Signoretti, Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET), Urologic Oncology: Seminars and Original Investigations, 2013, 31, 8, 1788

    CrossRef

  16. 16
    M L Maitland, K Wu, M R Sharma, Y Jin, S P Kang, W M Stadler, T G Karrison, M J Ratain, R R Bies, Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling, Clinical Pharmacology & Therapeutics, 2013, 93, 4
  17. 17
    Fausto Petrelli, Sandro Barni, Surrogate End Points and Postprogression Survival in Renal Cell Carcinoma: An Analysis of First-Line Trials With Targeted Therapies, Clinical Genitourinary Cancer, 2013, 11, 4, 385

    CrossRef

  18. 18
    Andrew Stein, Joaquim Bellmunt, Bernard Escudier, Dennis Kim, Sotirios G. Stergiopoulos, William Mietlowski, Robert J. Motzer, Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial, European Urology, 2013, 64, 6, 994

    CrossRef

  19. 19
    C Seidel, J Busch, S Weikert, S Steffens, C Bokemeyer, V Grünwald, Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC), British Journal of Cancer, 2013, 109, 12, 2998

    CrossRef

  20. 20
    Saadia A Aziz, Joshua Sznol, Adebowale Adeniran, John W Colberg, Robert L Camp, Harriet M Kluger, Vascularity of primary and metastatic renal cell carcinoma specimens, Journal of Translational Medicine, 2013, 11, 1, 15

    CrossRef

  21. 21
    Housam Haddad, Brian I. Rini, Current Treatment Considerations in Metastatic Renal Cell Carcinoma, Current Treatment Options in Oncology, 2012, 13, 2, 212

    CrossRef

  22. 22
    Aline Guillot, Antonin Levy, Cécile Pacaut, Olivier Collard, Christophe Massard, Yacine Merrouche, Nicolas Magné, Reappraisal of the Role of Bevacizumab in the Therapeutic Strategy in Advanced Renal Cell Carcinoma, Clinical Genitourinary Cancer, 2012, 10, 3, 147

    CrossRef

  23. 23
    Joost S. Vermaat, Frank L. Gerritse, Astrid A. van der Veldt, Wijnand M. Roessingh, Tatjana M. Niers, Sjoukje F. Oosting, Stefan Sleijfer, Jeanine M. Roodhart, Jos H. Beijnen, Jan H. Schellens, Jourik A. Gietema, Epie Boven, Dick J. Richel, John B. Haanen, Emile E. Voest, Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients, European Urology, 2012, 62, 4, 685

    CrossRef

  24. 24
    Daniel Keizman, Peng Huang, Mario A. Eisenberger, Roberto Pili, Jenny J. Kim, Emmanuel S. Antonarakis, Hans Hammers, Michael A. Carducci, Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination, European Journal of Cancer, 2011, 47, 13, 1955

    CrossRef

  25. You have free access to this content25
    Bernard Escudier, Progression-free survival as a surrogate marker of overall survival, Cancer, 2011, 117, 12
  26. 26
    Manish R. Sharma, Richard L. Schilsky, Role of randomized phase III trials in an era of effective targeted therapies, Nature Reviews Clinical Oncology, 2011, 9, 4, 208

    CrossRef

  27. 27
    Chris Coppin, Christian Kollmannsberger, Lyly Le, Franz Porzsolt, Timothy J. Wilt, Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials, BJU International, 2011, 108, 10
  28. 28
    V Grünwald, C Seidel, M Fenner, A Ganser, J Busch, S Weikert, Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies, British Journal of Cancer, 2011, 105, 11, 1635

    CrossRef